Information:
Fel:
ID
28438
Beskrivning
Study part: Neovascular AMD History Screening . A Phase III, Multicenter, Randomized, Double-Masked, Active Treatment-Controlled Study Of The Efficacy And Safety Of rhuFab V2 (Ranibizumab) Compared With Verteporfin (Visudyne®) Photodynamic Therapy In Subjects With Predominantly Classic Subfoveal Neovascular Age-Related Macular Degeneration.
Nyckelord
Versioner (1)
- 2018-01-13 2018-01-13 -
Rättsinnehavare
Roche
Uppladdad den
13 januari 2018
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Neovascular AMD History Screening rhuFab V2 Neovascular Age-Related Macular Degeneration FVF2587g
Neovascular AMD History Screening
- StudyEvent: ODM
Similar models
Neovascular AMD History Screening
- StudyEvent: ODM
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
NEOVASCULAR AMD HISTORY (SCREENING)
C0242383 (UMLS CUI-1)
C0262926 (UMLS CUI-2)
C0262926 (UMLS CUI-2)
Age related macular degeneration Right Eye
Item
Is Neovascular AMD present in the Right Eye?
boolean
C0242383 (UMLS CUI [1,1])
C0229089 (UMLS CUI [1,2])
C0229089 (UMLS CUI [1,2])
date of diagnosis
Item
If Yes, date when Neovascular AMD was first diagnosed in the Right Eye:
boolean
C2316983 (UMLS CUI [1])
Age related macular degeneration Left eye
Item
Is Neovascular AMD present in the Left Eye?
boolean
C0242383 (UMLS CUI [1,1])
C0229090 (UMLS CUI [1,2])
C0229090 (UMLS CUI [1,2])
date of diagnosis
Item
If Yes, date when Neovascular AMD was first diagnosed in the Left Eye:
date
C2316983 (UMLS CUI [1])